FOLD
Price
$5.73
Change
-$0.20 (-3.37%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
1.76B
30 days until earnings call
IMVT
Price
$16.00
Change
-$0.10 (-0.62%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
2.73B
36 days until earnings call
Interact to see
Advertisement

FOLD vs IMVT

Header iconFOLD vs IMVT Comparison
Open Charts FOLD vs IMVTBanner chart's image
Amicus Therapeutics
Price$5.73
Change-$0.20 (-3.37%)
Volume$255.69K
Capitalization1.76B
Immunovant
Price$16.00
Change-$0.10 (-0.62%)
Volume$25.02K
Capitalization2.73B
FOLD vs IMVT Comparison Chart in %
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. IMVT commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a StrongBuy and IMVT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (FOLD: $5.93 vs. IMVT: $16.10)
Brand notoriety: FOLD and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 185% vs. IMVT: 223%
Market capitalization -- FOLD: $1.76B vs. IMVT: $2.73B
FOLD [@Biotechnology] is valued at $1.76B. IMVT’s [@Biotechnology] market capitalization is $2.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, IMVT is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 4 TA indicator(s) are bullish while IMVT’s TA Score has 7 bullish TA indicator(s).

  • FOLD’s TA Score: 4 bullish, 3 bearish.
  • IMVT’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +5.14% price change this week, while IMVT (@Biotechnology) price change was +1.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

IMVT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.74B) has a higher market cap than FOLD($1.76B). IMVT YTD gains are higher at: -35.002 vs. FOLD (-37.049). FOLD has higher annual earnings (EBITDA): 53.6M vs. IMVT (-437.78M). IMVT has more cash in the bank: 714M vs. FOLD (251M). IMVT has less debt than FOLD: IMVT (98K) vs FOLD (443M). FOLD has higher revenues than IMVT: FOLD (543M) vs IMVT (0).
FOLDIMVTFOLD / IMVT
Capitalization1.76B2.74B64%
EBITDA53.6M-437.78M-12%
Gain YTD-37.049-35.002106%
P/E RatioN/AN/A-
Revenue543M0-
Total Cash251M714M35%
Total Debt443M98K452,041%
FUNDAMENTALS RATINGS
FOLD vs IMVT: Fundamental Ratings
FOLD
IMVT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9397
PRICE GROWTH RATING
1..100
8863
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5027

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (43) in the null industry is in the same range as FOLD (64) in the Biotechnology industry. This means that IMVT’s stock grew similarly to FOLD’s over the last 12 months.

IMVT's Profit vs Risk Rating (100) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (93) in the Biotechnology industry is in the same range as IMVT (97) in the null industry. This means that FOLD’s stock grew similarly to IMVT’s over the last 12 months.

IMVT's Price Growth Rating (63) in the null industry is in the same range as FOLD (88) in the Biotechnology industry. This means that IMVT’s stock grew similarly to FOLD’s over the last 12 months.

IMVT's P/E Growth Rating (100) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDIMVT
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
76%
Momentum
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
74%
MACD
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 25 days ago
77%
Declines
ODDS (%)
Bearish Trend 13 days ago
78%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LICSX17.320.16
+0.93%
Lord Abbett International Equity R4
WMFFX63.400.28
+0.44%
American Funds Washington Mutual F2
JSVZX23.300.03
+0.13%
JPMorgan Small Cap Value R2
HCYIX18.160.02
+0.11%
Hilton Tactical Income Instl
FGSKX58.23-0.07
-0.12%
Federated Hermes MDT Mid Cap Growth R6

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+4.22%
VCYT - FOLD
43%
Loosely correlated
+2.13%
IMVT - FOLD
43%
Loosely correlated
-1.77%
ROIV - FOLD
43%
Loosely correlated
-1.81%
ATXS - FOLD
42%
Loosely correlated
+2.39%
RARE - FOLD
42%
Loosely correlated
-2.43%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-1.77%
ROIV - IMVT
62%
Loosely correlated
-1.81%
OCUL - IMVT
51%
Loosely correlated
-2.54%
CGON - IMVT
50%
Loosely correlated
-0.46%
IDYA - IMVT
49%
Loosely correlated
-4.13%
XENE - IMVT
49%
Loosely correlated
+0.62%
More